EXEL:NASDAQ
Exelixis Inc
$59.15
arrow_upward
+1.06%(+0.62) 1D
Sep 3, 3:33:33 PM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for EXEL...
Open
$58.75
High
$59.72
Low
$58.20
Mkt. cap
14.66B
Avg. vol.
2.51M
Volume
1.11M
P/E ratio
18.58
52-wk high
$59.72
52-wk low
$33.76
EPS
$3.18
Beta
0.42
Shares outstanding
247.78M
No. of employees
1K
Open
$58.75
High
$59.72
Low
$58.20
Mkt. cap
14.66B
Avg. vol.
2.51M
Volume
1.11M
P/E ratio
18.58
52-wk high
$59.72
52-wk low
$33.76
EPS
$3.18
Beta
0.42
Shares outstanding
247.78M
No. of employees
1K
News stories
From web sources and news partners
Zacks
·
6 hours ago
Exelixis (EXEL) is a Top-Ranked Value Stock: Should You Buy?
Investor's Business Daily
·
1 day ago
Cancer Stock Breaks Out To Highs; Key FDA Action On Watch
Investing.com
·
1 day ago
Exelixis stock hits all-time high at 57.68 USD
TipRanks
·
2 days ago
Exelixis Secures Key Patent Victory, Extends Exclusivity
Profile
Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration for medullary thyroid cancer with clinical activity in several other types of metastatic cancer. Wikipedia
About Exelixis Inc
CEOMichael M. Morrissey
Employees1.08K
FoundedNov 15, 1994
HeadquartersAlameda, California, United States
SectorBiotechnology
Websiteexelixis.com